Abstract: The compounds are vesamicol (hydroxylated phencyclidine (PCP) isomer trans-2-(4-phenyl-piperidino)cyclohexanol) derivatives with anticholinergic properties termed herein "azavesamicols" in which the cyclohexyl group of vesamicol is replaced with a heterocycle of similar size, the piperidyl ring. The compounds bind to the vesamicol receptor, a cytoplasmically-oriented site on the cholinergic synaptic vesicle, which is associated with the vesicular transporter of acetylcholine.

Abstract: Disclosed are an oxychlorination catalyst comprising a carrier material, and a palladium compound, a copper compound and a vanadium compound which are supported on the carrier material; an oxychlorination catalyst comprising a carrier material, and a palladium compound, a copper compound, a vanadium compound and an alkaline earth metal compound which are supported on the carrier material; processes for preparing these catalysts; and a method for oxychlorination of an olefin or an aromatic hydrocarbon using one of these catalysts.

Abstract: A process for hydrodewaxing a hydrocarbon feedstock boiling above about 350.degree. F. by contacting the feedstock and hydrogen at a hydrogen pressure of from about 300 to about 2000 psig at a temperature of 400.degree. to 900.degree. F. and at a space velocity of about 0.1 to about 10.0 LHSV with a catalyst comprising about 0.1 to about 23 wt. % of an oxide of a Group VIII metal, such as nickel, or an oxide of a Group VIB metal, such as molybdenum; supported on a porous alumina support containing about 50 to about 85 wt. % of a crystalline alumino-silicate zeolite of the ZSM-5 type based on the weight of the support. The catalyst is further characterized by having greater than 60% of the pore volume between 45-600 Angstroms in the 70-200 Angstrom range. The process is especially useful for dewaxing lubricating oil basestocks.

Abstract: An FCC process and apparatus for atomizing heavy feed are disclosed. A liquid feed containing stacked asphaltenes is pressurized, and preferably heated, with a gas such as light hydrocarbons. Pressurized gas and liquid discharge at high velocity into an expansion chamber, where shear force and sudden expansion disrupt stacked structures. Preferably, some thermal conversion, visbreaking, occurs in the expansion chamber. The disrupted feed is discharged into an FCC reactor, preferably to the base of a riser reactor, with a lighter feed, such as a gas oil, added higher up in the riser. Improved atomization and vaporization of the heavy feed in the riser increases conversion and reduces coke make.

Abstract: In the process for the continuous preparation of aminoaryl or aminoalkyl .beta.-sulfatoethyl sulfones by reaction of the corresponding .beta.-hydroxyethyl sulfones with sulfuric acid in a molar ratio of 1:1 to 1:1.15 at temperatures above 120 .degree. C. a mixture of a .beta.-hydroxyethyl sulfone with sulfuric acid is supplied to a fluidized bed of end product produced by recycling and mechanical stirring. The mixture is reacted at 100.degree. to 200.degree. C.

Abstract: Zaragozic acids isolated from a culture of MF5465 have been subjected to photoreaction, then derivatized at the 4-keto position. The resulting derivatives are active as squalene synthetase inhibitors and are useful in the treatment of hypercholesterolemia.

Abstract: A process is disclosed for treating polyamide fiber containing materials which process comprises applying a benzofuran-2-one compound to the material in order to enhance its moulding stability. In addition, compositions containing a fluorescent whitening agent and a benzofuran-2-one, and optionally one or more dyes, are disclosed.

Abstract: Two processes are described for the preparation of the optically pure compounds of formula 1: ##STR1## in which R.sup.1 and R.sup.2 are e.g. alkyl, R.sup.3 and R.sup.4 are e.g. hydrogen and R.sup.5 is e.g. hydrogen. Both processes include, as key steps, the enantioselective hydrogenation of a C.dbd.C double bond and the regioselective formation of a dicarboxylic acid monoamide derivative. In one process a phenylitaconic acid derivative is asymmetrically hydrogenated to give an optically active (R)-benzylsuccinic acid which is then converted to a diester, said diester being converted to the monoamide compound of formula 1. In the second process, a phenylitaconic acid derivative is converted to its anhydride, and the anhydride is then converted to a monoamide which is then asymmetrically hydrogenated to give the compound of formula 1.

Abstract: This invention relates to the production of hydroxy-terminated polymers in the 2,000-20,000 MW range suitable for use as prepolymers in curing reactions with isocyanates to produce elastomers. The process involves the continuous addition over periods of 25-50 hours of an oxirane (monoepoxide) or a mixture of an oxirane and an oxetane to a reaction mixture, consisting of stoichiometric excesses of oxonium ion-forming catalyst such as BF.sub.3 -etherate and a diol initiator dissolved in an inert solvent. Under these conditions, chain extension of the diol occurs and the formation of cyclic oligomers and other impurities is minimised. The mole ratio of the initiator to catalyst is maintained at above 10:1 to suppress the formation of cationic terminal species on the growing polymer chain.

Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.

Abstract: A compound having the formula ##STR1## where X is a radical of myo-inositol or a radical of a configuration isomer thereof where at least one R is ##STR2## where Y is (1) oxygen, (2) a straight or branched alkyl with 1-10 carbon atoms, where Z is ##STR3## where A.sup.1 and A.sup.2 are the same or different and are hydrogen or methyl and n is 3-10, or ##STR4## where A.sup.1 and A.sup.2 are hydrogen or methyl and where m is 1-5, where R.sup.1 is hydrogen, straight or branched alkyl, aryl or alkaryl, alkoxy or aryloxy, where R.sup.2 is(1) R.sup.1,(2) hydroxyl, or(3) OZOCOR.sup.1,and where the remaining R is/are hydroxyl.

Abstract: An air cell comprising a cell container, a gas diffusion electrode which uses oxygen as an active material, and an air-inlet opening for communication with air outside the container. A porous film is provided to support the gas diffusion electrode, and an air-diffusing porous sheet impregnated with film-forming silicone is provided between the porous film and the air-inlet opening.

Abstract: .alpha.-Phenylacrylic acid derivatives I ##STR1## n=0 to 4; y=a;R.sup.1 =H; alkyl; alkenyl; alkynyl; substituted or unsubstituted cycloalkyl; vinyl or ethynyl when W is a direct bond;R.sup.2 =CN; alkenyl; alkynyl; substituted or unsubstituted cycloalkyl; substituted or unsubstituted alkyl;R.sup.3 =H; NO.sub.2 ; CN; halogen; alkyl; alkoxy; haloalkyl; haloalkoxy; alkylthio;or when n is 2, 3 or 4, two adjacent substituents R.sup.3 together form substituted or unsubstituted 1,3-butadien-1,4-diyl;R.sup.4 is phenyl which carries a radical --CR.sup.7 .dbd.NO--R.sup.8 and which may further carry one or two radicals;W=direct bond; oxygen; sulfur; substituted or unsubstituted nitrogen;and A can be an oxygen or sulfur radical.

Abstract: A modular arrangement for stacks of ion conducting electrolyte elements includes a plurality of solid state ion conducting electrolyte elements spaced apart and arranged into stacks and the stacks further arranged at regular intervals around a central plenum. A plurality of gas flow passageways are disposed in the spaces between the electrolyte elements to enable reactant gases to circulate between the elements. A pair of manifold plates are disposed on either side of the electrolyte elements and sandwich the elements therebetween.

Abstract: Describes terminally ethylenically unsaturated poly(alkyleneoxy) surfactant compounds of the general formula, R--O--(R'O).sub.m --(EO).sub.n-1 --CH.sub.2 CH.sub.2 --X, wherein R is the ethylenically unsaturated hydrocarbon group, e.g., allyl, R' is the bivalent radical derived from butylene oxide, E is the bivalent ethylene radical, m and n are numbers of from 10 to 15 and 10 to 40 respectively, and X is chloride, tertiaryamino, sulfonate, sulfate, phosphate, isethionate and alkali metal salts of the anionic groups. These surfactant compounds may be used in emulsion polymerization of ethylenically unsaturated, e.g., vinyl, monomers.

Abstract: The present invention is directed to polysubstituted fullerene moieties having a plurality of substituents thereon wherein the substituents are selected from the group consisting of hydroxy in combination with hydroxy, amino, oxide, nitro, organocarboxy, amide and mixtures thereof.

Abstract: There are provided novel and optically active 2,2-dimethyl-1,3-dioxin-4-ones which are useful as starting materials for physiologically active compounds, functional materials or the like. Provided are optically active 5,6-epoxyhexanoic acid esters and novel optically active 6-substituted tetrahydropyran-2-one derivatives.

Abstract: A process for the manufacture of brofaromine and analogues thereof by reaction of a trisubstitued phosphonium methyl dihydroquinone compound with a 1-(substituted carbonyl)-4-(substituted carbonyl)-piperidine with subsequent cyclization and hydrolysis of the remaining carbonyl substituent. The resulting prmary compound can be further interconverted between free and salt forms or between different salt forms as desired.

Abstract: Fluorine- and chlorine- and/or bromine-containing aromatic compounds are dechlorinated and/or debrominated with hydrogen in an industrially advantageous and selective manner, if the palladium catalyst is present in stationary phase and the aromatic compound in gas phase.

Abstract: Fibrinogen receptor antagonists of the formula: ##STR1## are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.